New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 20, 2014
08:02 EDTWXWuXi PharmaTech's Suzhou toxicology facility passes FDA inspection
WuXi PharmaTech announced that its toxicology facility in Suzhou recently passed a surveillance Good Laboratory Practice inspection by the FDA with no major observations. This was the first FDA GLP inspection in the facility's five years of operation. The inspection was extensive, lasting five days and including the review of numerous processes and the audit of four studies. WuXi's toxicology facility in Suzhou has completed 92 IND-enabling programs for global submissions.
News For WX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 21, 2015
19:20 EDTWXWuXi consortium to acquire Ambrx
A consortium consisting of entities affiliated with Fosun Pharmaceutical, HOPU Investments, CEL Healthcare Fund, and WuXi PharmaTech (WX) announced that it has signed a merger agreement to acquire Ambrx (AMBX). The transaction is expected to close in Q2. Chairman Chen Qiyu of Fosun Pharma said, "This joint acquisition will result in great synergy with [our] current R&D system and platform. Under the help of Fosun Pharma, Ambrx's business expanding in China will enable Chinese patients to get faster access to innovative therapeutic drugs." Ge Li, CEO of Wuxi, remarked, "This transaction will allow WuXi to broadly access Ambrx's best-in-class ADC platform and biologics development capabilities."
May 13, 2015
16:35 EDTWXWuXi PharmaTech backs FY15 non-GAAP EPS view $1.73-$1.78, consensus $1.76
Subscribe for More Information
16:33 EDTWXWuXi PharmaTech reports Q1 EPS 36c, consensus 32c
Reports Q1 revenue $180.0M, consensus $174.15M.
15:04 EDTWXNotable companies reporting after market close
Subscribe for More Information
08:06 EDTWXWuXi PharmaTech formes special committee to evaluate non-binding proposal
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use